Inspire Medical Systems, Inc.
INSPInspire Medical Systems, Inc. develops and commercializes medical devices for the treatment of sleep apnea. The company's flagship device, the Inspire Therapy system, uses neurostimulation technology to stimulate the hypoglossal nerve, helping to keep the airway open during sleep. Founded in 2007 and headquartered in Minneapolis, Minnesota, Inspire aims to provide an alternative to traditional sleep apnea treatments such as CPAP machines.
Company News
Inspire Medical Systems presented new clinical data at SLEEP 2026 demonstrating the effectiveness of its Inspire V hypoglossal nerve stimulation system for obstructive sleep apnea treatment. Key findings include significant reductions in hypoxic burden, improved cardiovascular outcomes compared to CPAP therapy, and higher patient adherence rates....
Inspire Medical Systems announced that its management team will participate in the Wells Fargo 2026 MedTech Innovation Spotlight on June 26, 2026 at 10:00 a.m. Eastern Time. The company, which develops minimally invasive solutions for obstructive sleep apnea treatment, will present via live webcast with a replay available for two weeks.
U.S. stock futures rose on Tuesday following President Trump's announcement of 'Project Freedom' to reopen commercial shipping through the Strait of Hormuz, amid US-Iran tensions. Key movers included Duolingo (down 12.77% despite beating estimates due to weak guidance), Pinterest (up 16.59% on strong Q1 results), AMD (up 1.94% ahead of earnings),...
Inspire Medical Systems announced it will release Q1 2026 financial results on May 4, 2026, followed by a management conference call at 5:00 p.m. ET. The company will discuss financial performance and recent business developments. A webcast will be available for investors, with a replay archived for two weeks.
The article identifies 9 oversold US stocks trading 30.7% to 66.3% below estimated fair value amid market volatility driven by Middle East tensions and inflation concerns. Using a value investing strategy based on sharp year-to-date declines, proximity to 52-week lows, oversold RSI signals, and undervaluation metrics, the analysis highlights stoc...
